Dr Mark Jackson
- Research Associate (Clinical Research Garscube)
telephone:
0141 330 3984
email:
Mark.Jackson.2@glasgow.ac.uk
Publications
2023
Halstead, S. K. et al. (2023) Serum anti‐GM2 and anti‐GalNAc‐GD1a ganglioside IgG antibodies are biomarkers for immune‐mediated polyneuropathies in cats. Journal of the Peripheral Nervous System, 28(1), pp. 32-40. (doi: 10.1111/jns.12529) (PMID:36573790)
2022
Koessinger, A. L. et al. (2022) Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 29(10), pp. 2089-2104. (doi: 10.1038/s41418-022-01001-3) (PMID:35473984) (PMCID:PMC9525582)
Halstead, S.K. et al. (2022) Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. Journal of Small Animal Practice, 63(2), pp. 104-112. (doi: 10.1111/jsap.13439) (PMID:34791652)
Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)
2021
Bavelaar, B. M. et al. (2021) Oligonucleotide-functionalized gold nanoparticles for synchronous telomerase inhibition, radiosensitization, and delivery of theranostic radionuclides. Molecular Pharmaceutics, 18(10), pp. 3820-3831. (doi: 10.1021/acs.molpharmaceut.1c00442) (PMID:34449222) (PMCID:PMC8493550)
2020
Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)
Gomez-Roman, N. , Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R. , Stevenson, K. H., Dongre, S. A. and Chalmers, A. J. (2020) Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Molecular Cancer Therapeutics, 19(2), pp. 575-589. (doi: 10.1158/1535-7163.MCT-18-1320) (PMID:31672763)
2019
Gilbert, H. T. J., Mallikarjun, V., Dobre, O. , Jackson, M. R. , Pedley, R., Gilmore, A. P., Richardson, S. M. and Swift, J. (2019) Nuclear decoupling is part of a rapid protein-level cellular response to high-intensity mechanical loading. Nature Communications, 10, 4149. (doi: 10.1038/s41467-019-11923-1) (PMID:31515493) (PMCID:PMC6742657)
Jackson, M. R. , Bavelaar, B. M., Waghorn, P. A., Gill, M. R., El-Sagheer, A. H., Brown, T., Tarsounas, M. and Vallis, K. A. (2019) Radiolabeled oligonucleotides targeting the RNA subunit of telomerase inhibit telomerase and induce DNA damage in telomerase-positive cancer cells. Cancer Research, 79(18), pp. 4627-4637. (doi: 10.1158/0008-5472.CAN-18-3594) (PMID:31311806)
2017
Waghorn, P. A., Jackson, M. R. , Gouverneur, V. and Vallis, K. A. (2017) Targeting telomerase with radiolabeled inhibitors. European Journal of Medicinal Chemistry, 125, pp. 117-129. (doi: 10.1016/j.ejmech.2016.09.028) (PMID:27657809) (PMCID:PMC5154340)
2016
Cho, I., Jackson, M. R. and Swift, J. (2016) Roles of cross-membrane transport and signaling in the maintenance of cellular homeostasis. Cellular and Molecular Bioengineering, 9(2), pp. 234-246. (doi: 10.1007/s12195-016-0439-6) (PMID:27335609) (PMCID:PMC4893050)
2013
Jackson, M.R. , Falzone, N. and Vallis, K.A. (2013) Advances in anticancer radiopharmaceuticals. Clinical Oncology, 25(10), pp. 604-609. (doi: 10.1016/j.clon.2013.06.004) (PMID:23870756)
Articles
Halstead, S. K. et al. (2023) Serum anti‐GM2 and anti‐GalNAc‐GD1a ganglioside IgG antibodies are biomarkers for immune‐mediated polyneuropathies in cats. Journal of the Peripheral Nervous System, 28(1), pp. 32-40. (doi: 10.1111/jns.12529) (PMID:36573790)
Koessinger, A. L. et al. (2022) Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 29(10), pp. 2089-2104. (doi: 10.1038/s41418-022-01001-3) (PMID:35473984) (PMCID:PMC9525582)
Halstead, S.K. et al. (2022) Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. Journal of Small Animal Practice, 63(2), pp. 104-112. (doi: 10.1111/jsap.13439) (PMID:34791652)
Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)
Bavelaar, B. M. et al. (2021) Oligonucleotide-functionalized gold nanoparticles for synchronous telomerase inhibition, radiosensitization, and delivery of theranostic radionuclides. Molecular Pharmaceutics, 18(10), pp. 3820-3831. (doi: 10.1021/acs.molpharmaceut.1c00442) (PMID:34449222) (PMCID:PMC8493550)
Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)
Gomez-Roman, N. , Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R. , Stevenson, K. H., Dongre, S. A. and Chalmers, A. J. (2020) Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Molecular Cancer Therapeutics, 19(2), pp. 575-589. (doi: 10.1158/1535-7163.MCT-18-1320) (PMID:31672763)
Gilbert, H. T. J., Mallikarjun, V., Dobre, O. , Jackson, M. R. , Pedley, R., Gilmore, A. P., Richardson, S. M. and Swift, J. (2019) Nuclear decoupling is part of a rapid protein-level cellular response to high-intensity mechanical loading. Nature Communications, 10, 4149. (doi: 10.1038/s41467-019-11923-1) (PMID:31515493) (PMCID:PMC6742657)
Jackson, M. R. , Bavelaar, B. M., Waghorn, P. A., Gill, M. R., El-Sagheer, A. H., Brown, T., Tarsounas, M. and Vallis, K. A. (2019) Radiolabeled oligonucleotides targeting the RNA subunit of telomerase inhibit telomerase and induce DNA damage in telomerase-positive cancer cells. Cancer Research, 79(18), pp. 4627-4637. (doi: 10.1158/0008-5472.CAN-18-3594) (PMID:31311806)
Waghorn, P. A., Jackson, M. R. , Gouverneur, V. and Vallis, K. A. (2017) Targeting telomerase with radiolabeled inhibitors. European Journal of Medicinal Chemistry, 125, pp. 117-129. (doi: 10.1016/j.ejmech.2016.09.028) (PMID:27657809) (PMCID:PMC5154340)
Cho, I., Jackson, M. R. and Swift, J. (2016) Roles of cross-membrane transport and signaling in the maintenance of cellular homeostasis. Cellular and Molecular Bioengineering, 9(2), pp. 234-246. (doi: 10.1007/s12195-016-0439-6) (PMID:27335609) (PMCID:PMC4893050)
Jackson, M.R. , Falzone, N. and Vallis, K.A. (2013) Advances in anticancer radiopharmaceuticals. Clinical Oncology, 25(10), pp. 604-609. (doi: 10.1016/j.clon.2013.06.004) (PMID:23870756)